Cinevista Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 4, 2025, 6:07 am

Quick Insight

Cinevista Ltd, operating in the Entertainment & Media industry, currently trades at ₹18.9 with a MarketCap of ₹109 Cr. The company boasts a robust Return on Equity (ROE) of 47.7% and a healthy Return on Capital Employed (ROCE) of 19.9%. Furthermore, its Operating Profit Margin (OPM) stands at an impressive 41.90%. However, Cinevista Ltd faces significant challenges, with a negative Net Profit of -₹32 Cr and a Price-to-Book Value (P/BV) ratio of -9.17x, indicating the market values its assets below book value.

One key strength of Cinevista Ltd lies in its high ROE and ROCE, reflecting efficient use of capital and strong profitability. Additionally, the company's substantial promoter holding of 67.43% signals confidence in its long-term prospects. On the flip side, the firm's negative Net Profit and low P/BV ratio raise concerns about its financial health and market perception. Looking ahead, Cinevista Ltd's outlook could improve with a strategic shift towards cost optimization and revenue diversification, while risks remain elevated due to its high borrowing levels and negative profit trajectory. Retail investors should closely monitor the company's efforts to turn around its financial performance and enhance shareholder value in the competitive Entertainment & Media sector.

Competitors of Cinevista Ltd

All Competitor Stocks of Cinevista Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:40 pm

Below is a detailed analysis of the quarterly data for Cinevista Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 4.63 Cr.. The value appears to be declining and may need further review. It has decreased from 11.47 Cr. (Mar 2025) to 4.63 Cr., marking a decrease of 6.84 Cr..
• For Expenses, as of Jun 2025, the value is 2.69 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 26.60 Cr. (Mar 2025) to 2.69 Cr., marking a decrease of 23.91 Cr..
• For Operating Profit, as of Jun 2025, the value is 1.94 Cr.. The value appears strong and on an upward trend. It has increased from -15.13 Cr. (Mar 2025) to 1.94 Cr., marking an increase of 17.07 Cr..
• For OPM %, as of Jun 2025, the value is 41.90%. The value appears strong and on an upward trend. It has increased from -131.91% (Mar 2025) to 41.90%, marking an increase of 173.81%.
• For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.03 Cr..
• For Interest, as of Jun 2025, the value is 0.90 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.92 Cr. (Mar 2025) to 0.90 Cr., marking a decrease of 0.02 Cr..
• For Depreciation, as of Jun 2025, the value is 0.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Mar 2025) to 0.05 Cr., marking a decrease of 0.01 Cr..
• For Profit before tax, as of Jun 2025, the value is 0.99 Cr.. The value appears strong and on an upward trend. It has increased from -16.08 Cr. (Mar 2025) to 0.99 Cr., marking an increase of 17.07 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 60.88% (Mar 2025) to 0.00%, marking a decrease of 60.88%.
• For Net Profit, as of Jun 2025, the value is 0.99 Cr.. The value appears strong and on an upward trend. It has increased from -25.87 Cr. (Mar 2025) to 0.99 Cr., marking an increase of 26.86 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.17. The value appears strong and on an upward trend. It has increased from -4.50 (Mar 2025) to 0.17, marking an increase of 4.67.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 4:00 pm

Growth

Last Updated: September 5, 2025, 2:00 am

Balance Sheet

Last Updated: September 10, 2025, 1:39 pm

Below is a detailed analysis of the balance sheet data for Cinevista Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 12.00 Cr..
• For Reserves, as of Mar 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 70.00 Cr. (Mar 2024) to 39.00 Cr., marking a decrease of 31.00 Cr..
• For Borrowings, as of Mar 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2024) to 25.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 70.00 Cr.. The value appears to be improving (decreasing). It has decreased from 72.00 Cr. (Mar 2024) to 70.00 Cr., marking a decrease of 2.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 146.00 Cr.. The value appears to be improving (decreasing). It has decreased from 178.00 Cr. (Mar 2024) to 146.00 Cr., marking a decrease of 32.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 125.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 103.00 Cr..
• For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 11.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2024) to 121.00 Cr., marking an increase of 81.00 Cr..
• For Total Assets, as of Mar 2025, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 178.00 Cr. (Mar 2024) to 146.00 Cr., marking a decrease of 32.00 Cr..

Notably, the Reserves (39.00 Cr.) exceed the Borrowings (25.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Cinevista Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 24, the value is -1.27. This value is below the healthy minimum of 5. It has increased from -4.75 (Mar 23) to -1.27, marking an increase of 3.48.
• For Diluted EPS (Rs.), as of Mar 24, the value is -1.27. This value is below the healthy minimum of 5. It has increased from -4.75 (Mar 23) to -1.27, marking an increase of 3.48.
• For Cash EPS (Rs.), as of Mar 24, the value is -1.26. This value is below the healthy minimum of 3. It has increased from -4.73 (Mar 23) to -1.26, marking an increase of 3.47.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is -1.99. It has decreased from -0.71 (Mar 23) to -1.99, marking a decrease of 1.28.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 13.94. It has decreased from 15.22 (Mar 23) to 13.94, marking a decrease of 1.28.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 0.07. It has decreased from 0.13 (Mar 23) to 0.07, marking a decrease of 0.06.
• For PBDIT / Share (Rs.), as of Mar 24, the value is -0.58. This value is below the healthy minimum of 2. It has increased from -6.50 (Mar 23) to -0.58, marking an increase of 5.92.
• For PBIT / Share (Rs.), as of Mar 24, the value is -0.60. This value is below the healthy minimum of 0. It has increased from -6.52 (Mar 23) to -0.60, marking an increase of 5.92.
• For PBT / Share (Rs.), as of Mar 24, the value is -1.12. This value is below the healthy minimum of 0. It has increased from -7.86 (Mar 23) to -1.12, marking an increase of 6.74.
• For Net Profit / Share (Rs.), as of Mar 24, the value is -1.27. This value is below the healthy minimum of 2. It has increased from -4.75 (Mar 23) to -1.27, marking an increase of 3.48.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -1.27. This value is below the healthy minimum of 2. It has increased from -4.75 (Mar 23) to -1.27, marking an increase of 3.48.
• For PBDIT Margin (%), as of Mar 24, the value is -784.10. This value is below the healthy minimum of 10. It has increased from -4,784.16 (Mar 23) to -784.10, marking an increase of 4,000.06.
• For PBIT Margin (%), as of Mar 24, the value is -805.26. This value is below the healthy minimum of 10. It has increased from -4,798.60 (Mar 23) to -805.26, marking an increase of 3,993.34.
• For PBT Margin (%), as of Mar 24, the value is -1,494.46. This value is below the healthy minimum of 10. It has increased from -5,789.27 (Mar 23) to -1,494.46, marking an increase of 4,294.81.
• For Net Profit Margin (%), as of Mar 24, the value is -1,702.56. This value is below the healthy minimum of 5. It has increased from -3,498.06 (Mar 23) to -1,702.56, marking an increase of 1,795.50.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is -1,702.56. This value is below the healthy minimum of 8. It has increased from -3,498.06 (Mar 23) to -1,702.56, marking an increase of 1,795.50.
• For Return on Networth / Equity (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 15. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Return on Capital Employeed (%), as of Mar 24, the value is -3.35. This value is below the healthy minimum of 10. It has increased from -33.96 (Mar 23) to -3.35, marking an increase of 30.61.
• For Return On Assets (%), as of Mar 24, the value is -4.20. This value is below the healthy minimum of 5. It has increased from -15.98 (Mar 23) to -4.20, marking an increase of 11.78.
• For Long Term Debt / Equity (X), as of Mar 24, the value is -2.02. This value is below the healthy minimum of 0.2. It has increased from -5.56 (Mar 23) to -2.02, marking an increase of 3.54.
• For Total Debt / Equity (X), as of Mar 24, the value is -2.06. This value is within the healthy range. It has increased from -5.56 (Mar 23) to -2.06, marking an increase of 3.50.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.00. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Current Ratio (X), as of Mar 24, the value is 0.28. This value is below the healthy minimum of 1.5. It has decreased from 0.36 (Mar 23) to 0.28, marking a decrease of 0.08.
• For Quick Ratio (X), as of Mar 24, the value is 0.05. This value is below the healthy minimum of 1. It has decreased from 0.09 (Mar 23) to 0.05, marking a decrease of 0.04.
• For Interest Coverage Ratio (X), as of Mar 24, the value is -1.14. This value is below the healthy minimum of 3. It has increased from -5.11 (Mar 23) to -1.14, marking an increase of 3.97.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -1.47. This value is below the healthy minimum of 3. It has increased from -2.68 (Mar 23) to -1.47, marking an increase of 1.21.
• For Enterprise Value (Cr.), as of Mar 24, the value is 129.83. It has increased from 89.34 (Mar 23) to 129.83, marking an increase of 40.49.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 294.73. This value exceeds the healthy maximum of 3. It has increased from 111.68 (Mar 23) to 294.73, marking an increase of 183.05.
• For EV / EBITDA (X), as of Mar 24, the value is -37.59. This value is below the healthy minimum of 5. It has decreased from -2.33 (Mar 23) to -37.59, marking a decrease of 35.26.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 243.81. This value exceeds the healthy maximum of 3. It has increased from 88.00 (Mar 23) to 243.81, marking an increase of 155.81.
• For Price / BV (X), as of Mar 24, the value is -9.17. This value is below the healthy minimum of 1. It has increased from -16.73 (Mar 23) to -9.17, marking an increase of 7.56.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 244.37. This value exceeds the healthy maximum of 3. It has increased from 88.13 (Mar 23) to 244.37, marking an increase of 156.24.
• For EarningsYield, as of Mar 24, the value is -0.06. This value is below the healthy minimum of 5. It has increased from -0.39 (Mar 23) to -0.06, marking an increase of 0.33.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness